Belite Bio (BLTE) News Today $60.36 +1.81 (+3.09%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$59.90 -0.46 (-0.77%) As of 06/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLTE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Belite Bio, Inc (NASDAQ:BLTE) Sees Large Growth in Short InterestBelite Bio, Inc (NASDAQ:BLTE - Get Free Report) saw a significant growth in short interest in May. As of May 31st, there was short interest totalling 118,200 shares, a growth of 31.8% from the May 15th total of 89,700 shares. Based on an average daily volume of 37,500 shares, the days-to-cover ratio is currently 3.2 days. Currently, 0.4% of the shares of the stock are sold short.June 17 at 6:33 PM | marketbeat.comBelite Bio (NASDAQ:BLTE) Sees Unusually-High Trading Volume - Should You Buy?Belite Bio (NASDAQ:BLTE) Sees Strong Trading Volume - What's Next?June 17 at 12:43 PM | marketbeat.comAnalysts Issue Forecasts for Belite Bio FY2026 EarningsJune 12, 2025 | americanbankingnews.comAnalysts Set Expectations for Belite Bio FY2026 EarningsBelite Bio, Inc (NASDAQ:BLTE - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Belite Bio in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Kim expects that the company will earn ($2.00) per share for the year. Cantor FitJune 11, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Sees Unusually-High Trading Volume - Here's What HappenedBelite Bio (NASDAQ:BLTE) Sees Unusually-High Trading Volume - Time to Buy?June 9, 2025 | marketbeat.comGAMMA Investing LLC Raises Stock Holdings in Belite Bio, Inc (NASDAQ:BLTE)GAMMA Investing LLC raised its position in shares of Belite Bio, Inc (NASDAQ:BLTE - Free Report) by 9,391.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 122,441 shares of the company's stock aftJune 9, 2025 | marketbeat.comBank of America Corp DE Acquires 4,891 Shares of Belite Bio, Inc (NASDAQ:BLTE)Bank of America Corp DE boosted its holdings in Belite Bio, Inc (NASDAQ:BLTE - Free Report) by 36.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 18,342 shares of the company's stock after acquiring an additional 4,891 shJune 7, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Stock Price Down 4.1% - Here's WhyBelite Bio (NASDAQ:BLTE) Stock Price Down 4.1% - What's Next?June 6, 2025 | marketbeat.comBelite Bio, Inc (NASDAQ:BLTE) Short Interest Up 23.0% in MayBelite Bio, Inc (NASDAQ:BLTE - Get Free Report) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 89,700 shares, a growth of 23.0% from the April 30th total of 72,900 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily volume of 41,500 shares, the days-to-cover ratio is currently 2.2 days.June 3, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Trading Up 5.3% - Should You Buy?Belite Bio (NASDAQ:BLTE) Trading 5.3% Higher - Still a Buy?May 30, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for Belite Bio Q1 Earnings?Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Belite Bio in a research note issued to investors on Wednesday, May 21st. HC Wainwright analyst Y. Chen anticipates that the company will earnMay 25, 2025 | marketbeat.comBelite Bio stock holds $80 target on FDA breakthrough nodMay 23, 2025 | investing.comBelite Bio (NASDAQ:BLTE) Shares Gap Up - Time to Buy?Belite Bio (NASDAQ:BLTE) Shares Gap Up - Here's WhyMay 23, 2025 | marketbeat.comBelite Bio, Inc: Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt DiseaseMay 21, 2025 | finanznachrichten.deBelite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt DiseaseMay 21, 2025 | globenewswire.comFY2025 EPS Estimates for Belite Bio Cut by Cantor FitzgeraldBelite Bio, Inc (NASDAQ:BLTE - Free Report) - Investment analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Belite Bio in a research note issued on Thursday, May 15th. Cantor Fitzgerald analyst J. Kim now expects that the company will post earnings of ($1.48May 21, 2025 | marketbeat.comQ2 Earnings Estimate for Belite Bio Issued By HC WainwrightBelite Bio, Inc (NASDAQ:BLTE - Free Report) - Analysts at HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for Belite Bio in a note issued to investors on Thursday, May 15th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.48) per share for the quarter,May 20, 2025 | marketbeat.comBelite Bio stock retains Overweight rating at Cantor FitzgeraldMay 17, 2025 | uk.investing.comWe're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash BurnMay 16, 2025 | finance.yahoo.comBelite Bio signals positive DSMB review and targets 500-patient PHOENIX trial enrollment completion in Q3 2025 while maintaining strong cash runwayMay 16, 2025 | msn.comBelite Bio Inc (BLTE) Q1 2025 Earnings Call Highlights: Strong Financial Position Amid Rising ...May 16, 2025 | finance.yahoo.comBelite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study ReadoutMay 15, 2025 | seekingalpha.comBelite Bio Advances Tinlarebant Trials with Positive Interim ResultsMay 14, 2025 | tipranks.comEarnings Outlook For Belite BioMay 14, 2025 | benzinga.comBelite Bio Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 13, 2025 | globenewswire.comBelite Bio, Inc to Present at the dbVIC – Deutsche Bank ADR Virtual Investor Conference May 15thMay 12, 2025 | financialpost.comBelite Bio, Inc to Present at the dbVIC – Deutsche Bank ADR Virtual Investor Conference May 15thMay 12, 2025 | financialpost.comBelite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15thMay 12, 2025 | globenewswire.comBelite Bio to Participate in Four Upcoming Investor ConferencesMay 12, 2025 | globenewswire.comBelite Bio, Inc American Depositary Shares (BLTE)May 10, 2025 | nasdaq.comBelite Bio (BLTE) to Release Quarterly Earnings on MondayBelite Bio (NASDAQ:BLTE) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-belite-bio-inc-stock/)May 7, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Sees Unusually-High Trading Volume - Time to Buy?Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading Volume - Still a Buy?May 1, 2025 | marketbeat.comBelite Bio, Inc (NASDAQ:BLTE) Shares Purchased by JPMorgan Chase & Co.JPMorgan Chase & Co. increased its holdings in shares of Belite Bio, Inc (NASDAQ:BLTE - Free Report) by 130.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,636 shares of the company's stock after acquiring anApril 30, 2025 | marketbeat.comBelite Bio, Inc (NASDAQ:BLTE) Sees Significant Drop in Short InterestBelite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the target of a significant decrease in short interest in March. As of March 31st, there was short interest totalling 70,000 shares, a decrease of 21.5% from the March 15th total of 89,200 shares. Based on an average daily trading volume, of 42,500 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.3% of the company's stock are sold short.April 21, 2025 | marketbeat.comLeerink Partnrs Expects Reduced Earnings for Belite BioBelite Bio, Inc (NASDAQ:BLTE - Free Report) - Leerink Partnrs reduced their FY2028 earnings per share estimates for Belite Bio in a research note issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of $4.40 for the year, downApril 18, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Stock Price Down 7.2% - Time to Sell?Belite Bio (NASDAQ:BLTE) Trading Down 7.2% - Here's WhyApril 11, 2025 | marketbeat.comBelite Bio, Inc. Appoints New AuditorMarch 28, 2025 | tipranks.comBelite Bio price target raised to $80 from $79 at BenchmarkMarch 27, 2025 | markets.businessinsider.comBelite Bio (NASDAQ:BLTE) Shares Gap Up - Here's What HappenedBelite Bio (NASDAQ:BLTE) Shares Gap Up - What's Next?March 27, 2025 | marketbeat.comBenchmark Reiterates Buy Rating for Belite Bio (NASDAQ:BLTE)Benchmark reissued a "buy" rating and issued a $80.00 target price on shares of Belite Bio in a research note on Wednesday.March 27, 2025 | marketbeat.comFY2025 EPS Forecast for Belite Bio Decreased by AnalystBelite Bio, Inc (NASDAQ:BLTE - Free Report) - Analysts at Cantor Fitzgerald lowered their FY2025 EPS estimates for shares of Belite Bio in a research note issued on Tuesday, March 18th. Cantor Fitzgerald analyst J. Kim now expects that the company will post earnings per share of ($1.36) for the yMarch 21, 2025 | marketbeat.comEquities Analysts Issue Forecasts for Belite Bio Q1 EarningsBelite Bio, Inc (NASDAQ:BLTE - Free Report) - Research analysts at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for Belite Bio in a report issued on Tuesday, March 18th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.37) per sharMarch 21, 2025 | marketbeat.comBelite Bio, Inc (NASDAQ:BLTE) Short Interest UpdateBelite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the target of a large growth in short interest in February. As of February 28th, there was short interest totalling 81,300 shares, a growth of 17.1% from the February 13th total of 69,400 shares. Based on an average trading volume of 46,300 shares, the days-to-cover ratio is currently 1.8 days. Currently, 0.3% of the company's stock are sold short.March 20, 2025 | marketbeat.comBelite Bio's (BLTE) "Overweight" Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Belite Bio in a report on Tuesday.March 19, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $100.00 target price on shares of Belite Bio in a research note on Tuesday.March 19, 2025 | marketbeat.comPromising Pipeline and Strategic Advancements: Marc Goodman Recommends ‘Buy’ for Belite Bio, Inc.March 19, 2025 | tipranks.comBelite Bio (NASDAQ:BLTE) Shares Gap Down on Disappointing EarningsBelite Bio (NASDAQ:BLTE) Shares Gap Down After Earnings MissMarch 18, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPSBelite Bio (NASDAQ:BLTE - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02).March 18, 2025 | marketbeat.comBelite Bio Advances in Retinal Disease Trials and Financial PositionMarch 18, 2025 | tipranks.comBelite Bio, Inc. (BLTE) Q4 2024 Earnings Call TranscriptMarch 17, 2025 | seekingalpha.com Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Email Address BLTE Media Mentions By Week BLTE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLTE News Sentiment▼1.200.69▲Average Medical News Sentiment BLTE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLTE Articles This Week▼42▲BLTE Articles Average Week Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RVMD News BBIO News ELAN News VRNA News LEGN News TGTX News GRFS News LNTH News TLX News NUVL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLTE) was last updated on 6/20/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe crypto summit that could change your life Right now, fear is rampant – creating the perfect buying oppo...Crypto 101 Media | SponsoredWar-Proof Power Why This "Weird" Government Land Auction Was No Ordinary Sale When 218,000 acres of land... smack in the m...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BLTE Stock Free BLTE Stock Alerts